Yonsei Cancer Center, Yonsei Cancer Research Institute, Seoul, Korea.
Cancer Res Treat. 2010 Dec;42(4):217-24. doi: 10.4143/crt.2010.42.4.217. Epub 2010 Dec 31.
We investigated the clinicopathologic information of patients with gastric cancer with multiple primary cancers (GC-MPC) of three or more sites.
Between 1995 and 2009, 105,908 patients were diagnosed with malignancy at Severance Hospital, Yonsei University Health System. Of these, 113 (0.1%) patients with MPC of three or more sites were registered, and 41 (36.3%) of these were GC-MPC. We retrospectively reviewed the clinical data and overall survival using the medical records of these 41 GC-MPC patients. We defined synchronous cancers as those occurring within 6 months of the first primary cancer, while metachronous cancers were defined as those occurring more than 6 months later.
Patients with metachronous GC-MPC were more likely to be female (p=0.003) and young than patients with synchronous GC-MPC (p=0.013). The most common cancer sites for metachronous GC-MPC patients were the colorectum, thyroid, lung, kidney and breast, while those for synchronous GC-MPC were the head and neck, esophagus, lung, and kidney. Metachronous GC-MPC demonstrated significantly better overall survival than synchronous GC-MPC, with median overall survival durations of 4.7 and 14.8 years, respectively, and 10-year overall survival rates of 48.2% and 80.7%, respectively (p<0.001).
Multiplicity of primary malignancies itself does not seem to indicate a poor prognosis. The early detection of additional primary malignancies will enable proper management with curative intent.
我们研究了三个或更多部位的胃癌多原发癌(GC-MPC)患者的临床病理信息。
1995 年至 2009 年间,在延世大学健康系统塞弗伦斯医院诊断出 105908 例恶性肿瘤患者。其中,113 例(0.1%)患者为三个或更多部位的多原发癌,其中 41 例(36.3%)为 GC-MPC。我们回顾性地审查了这些 41 例 GC-MPC 患者的临床数据和总生存情况。我们将同步癌定义为在第一个原发性癌症发生后 6 个月内发生的癌症,而异时癌则定义为发生在 6 个月以后的癌症。
与同步 GC-MPC 患者相比,患有异时 GC-MPC 的患者更有可能为女性(p=0.003)且年轻(p=0.013)。异时 GC-MPC 患者最常见的癌症部位是结直肠、甲状腺、肺、肾和乳房,而同步 GC-MPC 患者则是头颈部、食管、肺和肾。异时 GC-MPC 的总生存明显优于同步 GC-MPC,中位总生存时间分别为 4.7 年和 14.8 年,10 年总生存率分别为 48.2%和 80.7%(p<0.001)。
多发性原发性恶性肿瘤本身似乎并不能预示预后不良。早期发现额外的原发性恶性肿瘤将能够进行适当的以治愈为目的的管理。